Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)
Condition(s):Fibrosis; Focal Glomerulosclerosis; Kidney Failure; Nephrotic Syndrome; ProteinuriaLast Updated:May 26, 2014Completed
Hide Studies Not Open or Pending
Condition(s):Fibrosis; Focal Glomerulosclerosis; Kidney Failure; Nephrotic Syndrome; ProteinuriaLast Updated:May 26, 2014Completed
Condition(s):Diabetic Kidney Disease; Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2; Chronic Kidney Disease, Stage 3 (Moderate)Last Updated:October 28, 2022Recruiting
Condition(s):Heart FailureLast Updated:March 27, 2024Active, not recruiting
Condition(s):Renal Insufficiency, Chronic; Nephrotic SyndromeLast Updated:November 22, 2016Unknown status
Condition(s):Infection, Human Immunodeficiency Virus I; HIV InfectionLast Updated:April 12, 2011Completed
Condition(s):Aortic Valve Stenosis; Coronary Artery DiseaseLast Updated:September 9, 2021Completed
Condition(s):Chronic Kidney DiseaseLast Updated:January 5, 2016Unknown status
Condition(s):End Stage Renal Disease (ESRD)Last Updated:July 2, 2017Completed
Condition(s):Chronic Renal FailureLast Updated:May 30, 2023Completed
Condition(s):Kidney DiseasesLast Updated:March 4, 2024Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.